Malignant Hyperthermia in Dogs

  • Thomas E. Nelson
Conference paper


Our knowledge and understanding of the pharmacogenetic disease malignant hyperthermia (MH) has been significantly advanced through investigations of the porcine animal model. The distinction between “trigger” and “safe” anesthetics for MH-susceptible (MHS) human patients was originally based on the results of testing these drugs in the MHS pig [1,2]. The efficacy of dantrolene sodium for treating and preventing MH was discovered by Harrison [3] via experiments with MH pigs. Subsequent to its discovery in pigs, MHS was reported to occur in other species including the dog [4], cat [5], and horse [6]. Because MH in man represents a spectrum of susceptibility [7] and is genetically heterogenous [8], thorough investigations of MH among different animal species may provide important genetic and epigenetic information that will further advance our understanding of MH in man. In this chapter, I attempt to document the current state of knowledge regarding MH in dogs, focusing on the interesting genetic and phenotypic differences between MH in dogs and in pigs and how understanding the basis for these differences may have an impact on our understanding of MH in man.


Malignant Hyperthermia Malignant Hyperthermia Malignant Hyperthermia Susceptibility Dantrolene Sodium Skeletal Muscle Sarcoplasmic Reticulum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hall LW, Trim CM, Woolf N (1972) Further studies of porcine malignant hyperthermia. Br Med J 2: 145–148PubMedCrossRefGoogle Scholar
  2. 2.
    Harrison GG, Saunders SJ, Biebuyck JF, Hickman R, Dent DM, Weaver V, Terblanche J (1969) Anaesthetic-induced malignant hyperpyrexia and a method for its prediction. Br J Anaesth 41: 844–854PubMedCrossRefGoogle Scholar
  3. 3.
    Harrison GG (1975) Control of the malignant hyperpyretic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 47: 62–65PubMedCrossRefGoogle Scholar
  4. 4.
    Short CE, Paddleford RR (1973) Malignant hyperthermia in the dog. Anesthesiology 39: 462–463PubMedCrossRefGoogle Scholar
  5. 5.
    De Jong RH, Hoarner JE, Amory DW (1974) Malignant hyperthermia in the cat. Anesthesiology 41: 608–609PubMedCrossRefGoogle Scholar
  6. 6.
    McClure JJ (1975) Malignant hyperthermia in the horse. Minn Vet 15: 11–12Google Scholar
  7. 7.
    Nelson TE, Flewellen EH, Gloyna DF (1983) Spectrum of susceptibility of malignant hyperthermia: diagnostic dilemma. Anesth Analg 62: 545–552PubMedCrossRefGoogle Scholar
  8. 8.
    Levitt RC, Nouri N, Jedlicka AE, McKusick VA, Marks AR, Shuttack JG, Fletcher JE, Rosenberg H, Meyers DA (1991) Evidence for genetic heterogeneity in malignant hyperthermia. Genomics 11: 543–547PubMedCrossRefGoogle Scholar
  9. 9.
    Bagshaw RJ, Cox RH, Knight DH, et al (1978) Malignant hyperthermia in a greyhound.Google Scholar
  10. 10.
    Kirmayer AH, Klide AM, Purvance JE (1984) Malignant hyperthermia in a dog: case report and review of the syndrome. J Am Vet Med Assoc 185: 978–982PubMedGoogle Scholar
  11. 11.
    Leary SL, Anderson LC, Manning PJ, et al (1983) Recurrent malignant hyperthermia in a greyhound. J Am Vet Med Assoc 182: 521–522PubMedGoogle Scholar
  12. 12.
    O’Brien PI, Cribb PH, White RJ, et al (1983) Canine malignant hyperthermia: diagnosis of susceptibility in a breeding colony. Can Vet J 24: 172–177PubMedGoogle Scholar
  13. 13.
    Rand JS, O’Brien P (1987) Exercise-induced malignant hyperthermia in an English springer spaniel. J Am Vet Med Assoc 190: 1013–1014PubMedGoogle Scholar
  14. 14.
    Nelson TE (1991) Malignant hyperthermia in dogs. J Am Vet Med Assoc 198: 989–994PubMedGoogle Scholar
  15. 15.
    Britt BA, Kalow W (1970) Malignant hyperthermia: a statistical review. Can Anaesth Soc J 17: 293–315PubMedCrossRefGoogle Scholar
  16. 16.
    Nelson TE (1993) Pharmacogenetics and malignant hyperthermia. Anaesth Pharmacol Rev 1: 362–376Google Scholar
  17. 17.
    Nelson TE (1990) Porcine malignant hyperthermia: critical temperatures for in vivo and in vitro responses. Anesthesiology 73: 449–454PubMedCrossRefGoogle Scholar
  18. 18.
    Nelson TE (1987) Skeletal muscle sarcoplasmic reticulum in the malignant hyperthermia syndrome. In: Britt BA (ed) Malignant hyperthermia. Nijhoff, Boston, pp 4378Google Scholar
  19. 19.
    Jenden DJ, Fairhurst AS (1969) The pharmacology of ryanodine. Pharmacol Rev 21: 124Google Scholar
  20. 20.
    Chu AM, Diaz-Munoz M, Hawkes MJ, Brush K, Hamilton SL (1990) Ryanodine as a probe for the functional state of the skeletal muscle sarcoplasmic reticulum calcium release channel. Mol Pharmacol 37: 735–741PubMedGoogle Scholar
  21. 21.
    Fujii J, Otsu K, Zarzato S, de Leon VK, Khanna JE, Weiler JE, O’Brien PJ, MacLennan DH (1991) Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253: 448–451PubMedCrossRefGoogle Scholar
  22. 22.
    MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Worton RG (1990) Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343: 559–561PubMedCrossRefGoogle Scholar
  23. 23.
    McPherson PS, Campbell KP (1993) The ryanodine receptor/calcium release channel. J Biol Chem 268: 13675–13678Google Scholar
  24. 24.
    Nelson TE, Sweo T (1988) Ca“ uptake and Ca” release by skeletal muscle sarcoplasmic reticulum: differing sensitivity to inhalational anesthetics. Anesthesiology 69: 571577Google Scholar
  25. 25.
    Louis CF, Zualkernan K, Roghair T, Mickelson JR (1992) The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology 77: 114–125PubMedCrossRefGoogle Scholar
  26. 26.
    Nelson TE, Nelson KE (1990) Intra-and extrahumenal sarcoplasmic reticulum regulatory sites for Ca“-induced Ca” release. FEBS Lett 263: 292–294PubMedCrossRefGoogle Scholar
  27. 27.
    Nelson TE (1983) Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. J Clin Invest 72: 862–870PubMedCrossRefGoogle Scholar
  28. 28.
    Nelson TE, Levin M, Volpe P (1991) Evidence for intraluminal Ca“ regulatory site defect in sarcoplasmic reticulum from malignant hyperthermia pig muscle. J Pharmacol Exp Ther 256: 645–649PubMedGoogle Scholar
  29. 29.
    MacLennan DH, Phillips MS (1992) Malignant hyperthermia. Science 256: 789–794PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Thomas E. Nelson
    • 1
  1. 1.Department of Anesthesia, Bowman Gray School of MedicineWake Forest UniversityWinston-SalemUSA

Personalised recommendations